TEZSPIRE Market Summary
Key Factors Driving TEZSPIRE Growth
1. Demonstrated Clinical Value Across Broad Severe Asthma Populations
• TEZSPIRE has shown significant reductions in asthma exacerbations across biomarker subgroups, irrespective of eosinophil levels or allergic status — supporting treatment of a broad severe asthma population. This broad efficacy across patient types underpins strong adoption and prescriber confidence.
2. Strong and Growing Commercial Momentum
• In 2025, TEZSPIRE sales increased ~52% year-over-year, driven by volume growth as more patients initiated therapy.
• In the Q4 2025 period, TEZSPIRE generated ~USD 474 million in sales, a 60% year-over-year rise, with volume increases as the primary driver.
• Analysts have reported that the combined Amgen/AstraZeneca TEZSPIRE franchise likely generated between ~USD 1.5 billion and USD 2 billion in 2024 revenues globally, reflecting rapid market uptake following launch.
TEZSPIRE has moved beyond early launch phases into accelerating commercial growth, with double-digit volume expansion indicating expanding patient starts and market penetration.
3. Expanding Indications and Market Access
• The FDA has approved TEZSPIRE for chronic rhinosinusitis with nasal polyps, a second indication beyond severe asthma, greatly expanding its addressable patient pool.
• This label expansion taps into another large inflammatory disease category with unmet needs, strengthening long-term growth prospects and supporting broader commercial uptake.
4. Addressing Unmet Need and Broad Patient Eligibility
• Severe asthma affects a substantial global population, with many patients remaining uncontrolled on existing therapies. The broad eligibility of TEZSPIRE positions it as a key therapy for patients inadequately controlled on other biologics or those ineligible under biomarker-restricted labels.
• Physician surveys indicate persistent unmet need in severe asthma, especially in patients who have not achieved optimal control on other biologics, further boosting TEZSPIRE’s potential adoption.
5. Market Growth Tailwinds and Forecast Dynamics
• The global severe asthma treatment market — where TEZSPIRE competes — is large and growing, expected to expand from ~USD 24.3 billion in 2025 to ~USD 39.96 billion by 2035. Growth is driven by increasing diagnosis rates, biologic uptake, and unmet needs in refractory patients.
6. Differentiation Through Mechanism and Broad Efficacy
• TEZSPIRE’s mechanism of blocking thymic stromal lymphopoietin (TSLP) acts at the top of the inflammatory cascade, offering upstream modulation of multiple asthma pathways. This contrasts with more targeted biologics, helping expand its use across severe asthma phenotypes.
• Its broad label — without eosinophil or allergic phenotype restrictions — is a key differentiator and supports adoption as a first-or second-line biologic in clinical practice.
TEZSPIRE Recent Developments
• In March 2025, Amgen and AstraZeneca reported complete outcomes from the registrational Phase III WAYPOINT trial of TEZSPIRE for treating chronic rhinosinusitis with nasal polyps (CRSwNP).
The trial showed that treatment with the therapy decreased the severity of nasal polyps and congestion at week 52, as well as the need for surgery and the use of systemic corticosteroid.
• In October 2025, Amgen and AstraZeneca announced that the US Food and Drug Administration (FDA) approved TEZSPIRE® (tezepelumab-ekko) for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in adult and pediatric patients aged 12 years and older. TEZSPIRE is the first and only biologic approved for CRSwNP that targets thymic stromal lymphopoietin (TSLP).
“TEZSPIRE Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of TEZSPIRE for approved indication like Asthma and Rhinosinusitis; as well as potential indications like Chronic obstructive pulmonary disease; Eosinophilic oesophagitis, and Chronic urticaria in the 7MM. A detailed picture of TEZSPIRE’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the TEZSPIRE for approved and potential indications. The TEZSPIRE market report provides insights about TEZSPIRE’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current TEZSPIRE performance, future market assessments inclusive of the TEZSPIRE market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of TEZSPIRE sales forecasts, along with factors driving its market.
TEZSPIRE Drug Summary
TEZSPIRE (tezepelumab-ekko) is a first-in-class human monoclonal antibody (IgG2λ) that selectively inhibits thymic stromal lymphopoietin (TSLP), an epithelial cytokine upstream in Type 2 and non-Type 2 inflammatory pathways involved in severe asthma pathogenesis. Indicated as an add-on maintenance therapy for adults and adolescents aged 12 years and older with severe asthma inadequately controlled on high-dose inhaled corticosteroids plus another controller medication, it reduces exacerbations, improves lung function, and enhances asthma control regardless of eosinophil or FeNO levels; it is not for acute bronchospasm relief. Recently approved as add-on therapy with intranasal corticosteroids for severe chronic rhinosinusitis with nasal polyps (CRSwNP) in adults unresponsive to systemic corticosteroids or surgery, TEZSPIRE is administered subcutaneously every 4 weeks (210 mg via pre-filled pen or syringe) by healthcare professionals initially, with patients trainable for self-administration. The sterile, preservative-free solution contains tezepelumab-ekko (210 mg/1.91 mL) with inactive ingredients like glacial acetic acid, L-proline, polysorbate 80, sodium hydroxide, and water for injection. Developed by AstraZeneca and Amgen, it was FDA-approved for asthma in December 2021 and expanded for CRSwNP in 2025. The report provides TEZSPIRE’s sales, growth barriers and drivers, post usage and approvals in multiple indications.
Scope of the TEZSPIRE Market Report
The report provides insights into:
• A comprehensive product overview including the TEZSPIRE MoA, description, dosage and administration, research and development activities in approved indications like Asthma and Rhinosinusitis; as well as potential indications like Chronic obstructive pulmonary disease; Eosinophilic oesophagitis, and Chronic urticaria.
• Elaborated details on TEZSPIRE regulatory milestones and other development activities have been provided in TEZSPIRE market report.
• The report also highlights TEZSPIRE‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The TEZSPIRE market report also covers the patents information, generic entry and impact on cost cut.
• The TEZSPIRE market report contains current and forecasted TEZSPIRE sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The TEZSPIRE market report also features the SWOT analysis with analyst views for TEZSPIRE in approved and potential indications.
Methodology
The TEZSPIRE market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
TEZSPIRE Analytical Perspective by DelveInsight
• In-depth TEZSPIRE Market Assessment
This TEZSPIRE sales market forecast report provides a detailed market assessment of TEZSPIRE for approved indication like Asthma and Rhinosinusitis; as well as potential indications like Chronic obstructive pulmonary disease; Eosinophilic oesophagitis, and Chronic urticaria in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted TEZSPIRE sales data uptil 2034.
• TEZSPIRE Clinical Assessment
The TEZSPIRE market report provides the clinical trials information of TEZSPIRE for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.
TEZSPIRE Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
TEZSPIRE Market Potential & Revenue Forecast
• Projected market size for the TEZSPIRE and its key indications
• Estimated TEZSPIRE sales potential (TEZSPIRE peak sales forecasts)
• TEZSPIRE Pricing strategies and reimbursement landscape
TEZSPIRE Competitive Intelligence
• Number of competing drugs in development (pipeline analysis)
• TEZSPIRE Market positioning compared to existing treatments
• TEZSPIRE Strengths & weaknesses relative to competitors
TEZSPIRE Regulatory & Commercial Milestones
• TEZSPIRE Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity
TEZSPIRE Clinical Differentiation
• TEZSPIRE Efficacy & safety advantages over existing drugs
• TEZSPIRE Unique selling points
TEZSPIRE Market Report Highlights
• In the coming years, the TEZSPIRE market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The TEZSPIRE companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence TEZSPIRE’s dominance.
• Other emerging products for Asthma and Rhinosinusitis; as well as potential indications like Chronic obstructive pulmonary disease; Eosinophilic oesophagitis, and Chronic urticaria are expected to give tough market competition to TEZSPIRE and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of TEZSPIRE in approved and potential indications.
• Analyse TEZSPIRE cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted TEZSPIRE sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of TEZSPIRE in approved and potential indications.
Key Questions
• What is the class of therapy, route of administration and mechanism of action of TEZSPIRE? How strong is TEZSPIRE’s clinical and commercial performance?
• What is TEZSPIRE’s clinical trial status in each individual indications such as Asthma and Rhinosinusitis; as well as potential indications like Chronic obstructive pulmonary disease; Eosinophilic oesophagitis, and Chronic urticaria and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the TEZSPIRE Manufacturers?
• What are the key designations that have been granted to TEZSPIRE for approved and potential indications? How are they going to impact TEZSPIRE’s penetration in various geographies?
• What is the current and forecasted TEZSPIRE market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of TEZSPIRE in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to TEZSPIRE for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is TEZSPIRE? What is the duration of therapy and what are the geographical variations in cost per patient?
